$0.60
+0.03 (+5.37%)
Open$0.56
Previous Close$0.57
Day High$0.61
Day Low$0.55
52W High$7.29
52W Low$0.40
Volume—
Avg Volume1.82M
Market Cap54.64M
P/E Ratio—
EPS$-0.80
SectorBiotechnology
Analyst Ratings
Hold
16 analysts
Price Target
+1,880.6% upside
Current
$0.60
$0.60
Target
$11.82
$11.82
$9.31
$11.82 avg
$19.97
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 207.2K | 786.3K | 11.28M |
| Net Income | -82,571,913 | -282,029,304 | 2.04M |
| Profit Margin | -39,009.5% | -37,059.0% | 18.1% |
| EBITDA | -85,741,780 | -309,125,962 | 2.88M |
| Free Cash Flow | — | — | 1.40M |
| Rev Growth | -73.7% | -73.7% | +22.8% |
| Debt/Equity | 0.01 | 0.01 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |